European Journal of Cancer
Volume 46, Issue 1 , Pages 180-190 , January 2010

Interferon-λ induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents

  • Quanhai Li

      Affiliations

    • Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba 260-8717, Japan
    • ,
  • Kiyoko Kawamura

      Affiliations

    • Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba 260-8717, Japan
    • ,
  • Guangyu Ma

      Affiliations

    • Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba 260-8717, Japan
    • Department of Environmental Biochemistry, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
    • ,
  • Fumi Iwata

      Affiliations

    • Department of Nutritional Physiology, Faculty of Pharmaceutical Science, Josai University, 1-1 Keyakidai, Sakado 350-0295, Japan
    • ,
  • Muneo Numasaki

      Affiliations

    • Department of Nutritional Physiology, Faculty of Pharmaceutical Science, Josai University, 1-1 Keyakidai, Sakado 350-0295, Japan
    • ,
  • Nobuo Suzuki

      Affiliations

    • Department of Environmental Biochemistry, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
    • ,
  • Hideaki Shimada

      Affiliations

    • Division of Gastroenterological Surgery, Chiba Cancer Center, Chiba, 666-2 Nitona, Chuo-ku, Chiba 260-8717, Japan
    • ,
  • Masatoshi Tagawa

      Affiliations

    • Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba 260-8717, Japan
    • Corresponding Author InformationCorresponding author: Tel.: +81 43 264 5431x 5101; fax: 81 43 265 4459.

Received 24 August 2009 ,Accepted 1 October 2009.

References 

  1. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69–77
  2. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63–68
  3. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 2006;25:373–381
  4. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003;8:237–249
  5. Brand S, Beigel F, Olszak T, et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol. 2005;289:G960–G968
  6. Lasfar A, Lewis-Antes A, Smirnov SV, et al. Characterization of the mouse IFN-λ ligand-receptor system: IFN-λs exhibit antitumor activity against B16 melanoma. Cancer Res. 2006;66:4468–4477
  7. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131:1887–1898
  8. Coccia EM, Severa M, Giacomini E, et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol. 2004;34:796–805
  9. Mennechet FJ, Uzé G. Interferon-λ-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood. 2006;107:4417–4423
  10. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitumor activity of IFN-λ in murine tumor models. J Immunol. 2006;176:7686–7694
  11. Numasaki M, Tagawa M, Iwata F, et al. IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol. 2007;178:5086–5098
  12. Zitzmann K, Brand S, Baehs S, et al. Novel interferon-λs induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun. 2006;344:1334–1341
  13. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine. 2005;31:109–118
  14. Dumoutier L, Tounsi A, Michiels T, et al. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-λ1: similarities with type I interferon signaling. J Biol Chem. 2004;279:32269–32274
  15. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol. 2004;76:314–321
  16. Uzé G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie. 2007;89:729–734
  17. Parmar S, Platanias LC. Interferons: mechanisms of action and clinical applications. Curr Opin Oncol. 2003;15:431–439
  18. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26:112S–121S
  19. Fushimi K, Iijima M, Gao C, et al. Transformation of normal human fibroblasts into immortalized cells with the mutant p53 gene and x-rays. Int J Cancer. 1997;70:135–140
  20. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002;1:639–649
  21. Van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity. 2006;25:361–372
  22. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400–414
  23. Caraglia M, Marra M, Pelaia G, et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol. 2005;202:323–335
  24. Wong LH, Krauer KG, Hatzinisiriou I, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3γ. J Biol Chem. 1997;272:28779–28785
  25. Caraglia M, Leardi A, Corradino S, et al. α-interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. Int J Cancer. 1995;61:342–347
  26. Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003;424:516–523
  27. Porta C, Hadj-Slimane R, Nejmeddine M, et al. Interferons α and γ induce p53-dependent and p53-independent apoptosis, respectively. Oncogene. 2005;24:605–615
  28. Xiao S, Li D, Zhu HQ, et al. RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc Natl Acad Sci USA. 2006;103:16448–16453
  29. Sangfelt O, Erickson S, Castro J, et al. Molecular mechanisms underlying interferon-α-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene. 1999;18:2798–2810
  30. Sangfelt O, Erickson S, Einhorn S, Grandér D. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines. Oncogene. 1997;14:415–423
  31. Li W, Lewis-Antes A, Huang J, Balan M, Kotenko SV. Regulation of apoptosis by type III interferons. Cell Prolif. 2008;41:960–979
  32. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008;4:e1000017
  33. Levraud JP, Boudinot P, Colin I, et al. Identification of the zebrafish IFN receptor: implications for the origin of the vertebrate IFN system. J Immunol. 2007;178:4385–4394
  34. Maher SG, Sheikh F, Scarzello AJ, et al. IFNα and IFNλ differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther. 2008;7:1109–1115
  35. Ilson DH, Sirott M, Saltz L, et al. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer. 1995;75:2197–2202

PII: S0959-8049(09)00727-8

doi: 10.1016/j.ejca.2009.10.002

European Journal of Cancer
Volume 46, Issue 1 , Pages 180-190 , January 2010

Article Tools

* Image Usage & Resolution